In platinum-resistant ovarian cancer,
Glucocorticoid receptor activation opens a new perspective on chemoresistance
Science that aims to
reach more women
Science that aims to reach more women
Emerging research elucidates a unique resistance mechanism in ovarian cancer1
Platinum-resistant ovarian cancer (PROC) is an aggressive disease with poor prognosis and limited treatment options.² Biomarker-targeted treatments are available, but not all women are eligible.3,4
PROC by the numbers
~85%
of patients will experience recurrence and become resistant to chemotherapy5
3-7 months
median progression-free survival with current treatment options6
~64%
are not eligible for FDA-approved biomarker therapy3
An evolving scientific paradigm
Emerging research brings hope for clearer understanding
New science is shedding light on mechanisms of resistance. Studies have shown that chemotherapy
activity can be limited by cortisol-driven activation of the glucocorticoid receptor (GR), even at
physiological levels of cortisol.7
References:
1. Veneris JT, Darcy KM, Mhawech-Fauceglia P, et al. Gynecol Oncol. 2017;146(1):153-160. 2. Greer A, Gockley A, Manning-Geist B, et al. Int J Gynecol Cancer. 2021;31(10):1341-1347. 3. Matulonis UA, Lorusso D, Oaknin A, et al. J Clin Oncol. 2023;41(13):2436-2445. 4. FDA approves mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. FDA. March 22, 2024. Accessed December 11, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant-epithelial-ovarian 5. St Laurent J, Liu JF. J Clin Oncol. 2024;42(2):127-133. 6. Richardson DL, Eskander RN, O'Malley DM. JAMA Oncol. 2023;9(6):851-859. 7. Colombo N, Van Gorp T, Matulonis UA, et al. J Clin Oncol. 2023;41(30):4779-4789.
Dive deeper
Women need
more options
Despite advancements,
prognosis remains poor.4
Explore Unmet Needs in PROC
What is GR
activation?
See how glucocorticoid receptor
activation can suppress apoptosis and impact resistance.1
Discover GR Activation
Resource
Hub
Enhance your understanding
of GR signaling, disease
management, and more.
Discover Resources
Subscribe to
The Signal
Stay informed about the
latest science and join
The Signal newsletter.
Subscribe
